Company Overview

Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, our GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Our main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic and provide a long term cure to patients that does not require the use of immuno-suppression.

Our corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to our shareholders.

William L. Rust, Ph.D. CEO and Founder

William L. Rust, Ph.D. serves as Seraxis CEO and President. He developed the company’s technological assets and strategy. Prior to launching Seraxis, Dr. Rust lead a number of high performing teams and was instrumental in the development of therapeutic pancreatic and cardiac cells from embryonic stem cells in one of the early laboratories to take this approach. From previous managerial positions in the industry, he has a history of delivering results, meeting corporate milestones and growing company operations. Dr. Rust is a forward thinker and visionary and, after 17 years experience, is well connected in the field of stem cells and regenerative medicine.

Carole A. Welsch, Ph.D., M.B.A.—Chief Business Officer

Carole A. Welsch, Ph.D. M.B.A. has over 18 years of experience in the pharmaceutical and biotech industry. Prior to joining Seraxis, she led clinical trial, business development and commercial launch efforts at a number of companies including Novartis, QIAGEN and Vanda Pharmaceuticals. She currently oversees all matters related to finance, non-dilutive fund raising, and regulatory strategy for the organization. She is also instrumental in the execution of corporate partnerships, the management of Seraxis intellectual property portfolio and equity-based fund raising. She holds a Ph.D. In Molecular Biology from University Louis Pasteur, and an M.B.A. from Nanyang Business School.

Board of Directors

Seraxis benefits from the guidance from an experienced Board of Directors, made of five Directors with broad expertise and connection in the pharmaceutical, biotechnology, and investment management industries.

Sanjay Sehgal, M.B.A., Chairman

Sanjay Sehgal is the founder Managing Partner and CEO of East West Capital Partners (EWCP), a private equity and corporate finance advisory firm. In addition to Seraxis, Sanjay is also on the Board of Braidlock Ltd. He recently served on the Board of ITL Ltd and is on the steering committee of LiPlasome A/S. He is also a member of the President’s Leadership Council of the Hepatitis B Foundation, Baruch S. Blumberg Institute and the Pennsylvania Biotechnology Center. Prior to EWCP, Sanjay was a partner and member of the investment committee at Symphony Capital Partners (f.k.a Schroder Capital Partners), which managed in excess of US$860 million. Sanjay has served as the elected Hon. Treasurer and Hon. Secretary of the Singapore Venture Capital and Private Equity Association. He is an accomplished speaker and has spoken at over 40 different private equity and healthcare conferences across the world. Sanjay has a Master of Science (M.Sc.) from Columbia University, New York. He received his MBA, with distinction, in finance and multinational management from Wharton School of the University of Pennsylvania.

William Rust, Ph.D., Director

Dr. Rust is both an active member of the Board of Directors and a shareholder in the company. He has successfully raised several rounds of private equity funding to support Seraxis growing operations. Dr. Rust works with other members of the Board to design a long-term corporate strategy that delivers maximum value to shareholders while keeping on target the SERAXIS mission of curing type 1 diabetes.

Bernie Treidl, M.B.A., Director

Bernie Treidl has spent more than 30 years in the biotechnology industry starting, operating and guiding biotech companies. Prior to being a Seraxis director, Bernie was co-founder, President and CEO of ChemGen Corp. a biotech company that developed a fermentation process to make a key AIDS drug intermediate and later focused on the development and manufacture of enzymes used to improve the efficiency of meat-animal production. Bernie holds a B.A.Sc. and M.Eng. in Electrical Engineering from the University of Toronto and an MBA from Harvard Business School.

Jonathan Legg, Director

Jonathan Legg is Managing Director, Private Wealth Advisor and Principal of the Legg Wealth Management Group at Morgan Stanley Private Wealth Management since 1999. Jonathan began his career in the financial services industry over twenty years ago at Legg Mason Wood Walker, Inc. While there, he served as Vice President, Investments, and was the youngest broker to join the Chairman’s Council, the President’s Council, and the Advisory Board, which represents the top 1% of the firm’s financial advisors. From there, he founded the Private Client Group at Friedman, Billings & Ramsey (FBR) and served as Managing Director. Jonathan is an active member of the venture capital community as a limited partner in several private equity and venture capital funds, specifically the Maryland Angels Council, eMedia Club and the Dinner Club. Jonathan graduated from both The Woodberry Forest School and The College of William and Mary. He is involved in the College of William & Mary Annual Fund, and the Woodberry Forest School Advisory Board.

Gi-Hyeok Yang, Ph.D., Director

Gi-Hyeok Yang is Vice President, MedyTox Inc. Prior to this role, he served as senior managing director and executive director of MedyTox Inc. In addition to being on Seraxis Board, Gi-Hyeok also serves as a member of the Board of MedyTox Inc. He completed post-doctoral fellowships at both Michigan State University and the Korea Research Institute of Bioscience and Biotechnology. Gi-Hyeok holds a Ph.D. from the Korea Advanced Institute of Science and Technology (KAIST).

Scientific Advisors

Marie Csete, M.D., Ph.D.

Professor of Anesthesiology, USC Keck School of Medicine. Visiting Associate, Caltech Medical Engineering. Director Transplant Anesthesiology (former): UCSF, UCLA, Emory. Founding Director (former), Emory-Georgia Tech Human Embryonic Stem Cell Core. Former CSO, California Institute for Regenerative Medicine. CSO, Huntington Medical Research Institutes (former).

Giuseppe Orlando, M.D., Ph.D.

Assistant Professor, Wake Forest School of Medicine. Transplant surgeon scientist, specializing in kidney and pancreas transplantation, and organ bioengineering, regeneration and repair.

Carani Sanjeevi, M.D., Ph.D.

Professor, Karolinska Institute Division of Rheumatology, Karolinska University Hospital. Head of Molecular Immunogenetics Group, Center of Molecular Medicine, Karolinska University Hospital, Stockholm.

Business Development

Seraxis is keen on developing long-term strategic partnerships with organizations interested in bringing novel therapies to patients. Seraxis invites proposals of scientific collaborations and licensing opportunities around either of its technologies, across geographies and indications.

Interested parties may contact our Business Development Team.